← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Proton pump inhibitors
pantoprazole
A02BC02
Forms & Strengths
- Delayed-release oral tablet: 20 mg, 40 mg
- Delayed-release oral suspension: 40 mg packet
- Intravenous injection: 40 mg/vial
Adult Dosing
- Gastroesophageal Reflux Disease (GERD): 40 mg orally once daily for up to 8 weeks
- Erosive Esophagitis Maintenance: 20 to 40 mg orally once daily
- Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison): 40 mg orally twice daily, titrated up to 240 mg daily
Pediatric Dosing
- GERD/Erosive Esophagitis (ages 5 years and older): 20 mg daily for weights 15 kg to <40 kg; 40 mg daily for weights >=40 kg
Indications
- Short-term treatment of erosive esophagitis associated with GERD
- Maintenance of healing of erosive esophagitis
- Pathological hypersecretory conditions including Zollinger-Ellison syndrome
Mechanism of Action
- Proton pump inhibitor (PPI) that covalently binds to the H+/K+ ATPase enzyme system on the secretory surface of gastric parietal cells, suppressing the final step of acid production.
Contraindications
- Known hypersensitivity to substituted benzimidazoles or any component of the formulation
- Concomitant use with rilpivirine-containing products
Adverse Reactions
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
- Flatulence
- Dizziness
- Arthralgia
Drug Interactions
- Drugs pH-dependent for absorption (e.g., ketoconazole, iron salts, dasatinib): decreased absorption
- Warfarin: increased INR and prothrombin time monitoring recommended
- Methotrexate: potential increased methotrexate toxicity
- Clopidogrel: potentially reduced antiplatelet effect
- CYP2C19 inhibitors/inducers may alter pantoprazole exposure
Curated Content: Needs Vetting Before Put to Clinical Use